Although trastuzumab (Herceptin, Genentech Inc., San Francisco, CA) is an approved therapy for treating HER-2 dependent cancers, the development of trastuzumab resistance occurred within one year after the patients received the initial response to trastuzumab [30]. This evidence concerns the gene ERBB2 and cancer.